| |
Home »
News » 01/06 »
Roche and GlaxoSmithKline get bone strengthening injection approved
Roche and GlaxoSmithKline get bone strengthening injection
approved
Date published: 10/01/2006
The US
Food and Drug Administration (FDA) has approved an injected treatment for
sufferers of osteoporosis. Boniva, marketed by both
GlaxoSmithKline (GSK) and
Roche, is the first
bisphosphonate drug which can be administered quarterly to people with
postmenopausal osteoporosis. Clinical trails showed that it reduced new
fractures and increased bone density.
The drug was already approved in
its oral form, but GSK and Roche hope that the 15-30 second injected version
will be adopted by individuals who had trouble meeting dosage requirements
which include sitting upright for 30 to 60 minutes. Trials of the injected
version also showed higher increases in bone mineral density than the oral
version.
Robert R Recker, a Boniva trial investigator, said that the
drug "represents an important new opportunity to bring the bone-strengthening
benefits of Boniva to more women - including those who have difficulty with
dosing requirements of oral bisphosphonates."
Judith Cranford,
executive director of the National Osteoporosis Foundation, added: "Osteoporosis is a
serious, widespread and growing public health threat. We welcome any new
treatment options such as Boniva injection that will help patients address this
all too prevalent disease."
Osteoporosis affects ten million
individuals in the US, eight million of whom are women.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|